Droste-Med-E, Drostanolone Enanthate, 250 mg/ml, 10 ml

Drostanolone Enanthate 250 mg/ml by Bioniche Pharma is an extended-release parenteral anabolic formulation belonging to the dihydrotestosterone (DHT) family. Formulated by Bioniche Pharma with an enanthate ester to ensure sustained active release, Bioniche Pharma Drostanolone Enanthate provides strong intrinsic androgenic potency combined with natural anti-aromatase properties, making it an efficient agent for fostering lean, defined tissue without estrogenic fluid retention.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

Drostanolone Enanthate by Bioniche Pharma operates via selective interaction with cellular androgen receptors, driving intracellular nitrogen conservation and protein synthesis. Administration of exogenous androgens via Bioniche Pharma Drostanolone Enanthate suppresses pituitary gonadotropin release, inhibiting endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback regulation. Structurally, Bioniche Pharma Drostanolone Enanthate acts as a potent estrogen antagonist and does not undergo aromatization, preventing estrogen-dependent side effects such as fluid accumulation, gynecomastia, and secondary hypertension.

INDICATIONS & CLINICAL USE

• Rapid recovery and restoration of skeletal muscle tissue suffering from atrophy following severe physical trauma or injury using Bioniche Pharma formulations.
• Therapeutic support to counter muscle catabolism and cachexia associated with chronic wasting conditions under Bioniche Pharma care protocols.
• Adjunctive management for specific refractory anemias failing standard therapy using Bioniche Pharma anabolic support.
• Palliative estrogen-antagonistic therapy in select hormone-dependent advanced breast carcinoma cases under clinical supervision.

CONTRAINDICATIONS

• Contraindicated in women, children, adolescents, and elderly individuals. Strictly prohibited during pregnancy or planned pregnancy due to severe risks of female fetal masculinization.
• Male patients presenting with diagnosed or suspected carcinoma of the prostate gland, testes, or male breast cancer.
• Patients with active renal failure, nephrotic syndrome, or the nephrotic phase of nephritis.
• Diagnosed hypercalcemia, severe hepatic dysfunction, or underlying cardiovascular conditions including hypertension, previous stroke, or ischemic heart disease.
• Known hypersensitivity or allergic response to Drostanolone Enanthate, carrier oils, or inactive compounding excipients in Bioniche Pharma formulations.

PRECAUTIONS & PATIENT MONITORING

• Hepatic Surveillance: Elevated liver transaminases (AST, ALT, AP) and serum bilirubin may occur; periodic liver function panels are required during Bioniche Pharma therapy.
• Lipid & Cardiovascular Impact: Exogenous anabolic-androgenic agents elevate LDL cholesterol while reducing HDL cholesterol fractions. Baseline and periodic monitoring of serum lipid panels (total cholesterol, HDL, LDL, triglycerides) is recommended during Bioniche Pharma treatment.
• Coagulation Parameters: Bioniche Pharma Drostanolone Enanthate may suppress clotting factors II, V, VII, and X, prolonging prothrombin time (PT/INR). Patients taking oral anticoagulants (e.g., warfarin) require close oversight and potential dose adjustments.
• Prostatic Examinations: Male patients over 40 years should undergo digital rectal examinations and serum Prostate Specific Antigen (PSA) screening prior to and during Bioniche Pharma therapy.
• Comprehensive Lab Monitoring: Regular laboratory evaluation during Bioniche Pharma administration should include hemoglobin/hematocrit levels, total/free/bioavailable testosterone, dihydrotestosterone, and serum estradiol levels.

ADVERSE REACTIONS

• Male & Endocrine: Frequent erections, priapism, reduced sperm count (oligospermia), pituitary gonadotropin suppression, and shifts in libido associated with Bioniche Pharma Drostanolone Enanthate.
• Dermatological: Acne vulgaris, elevated sebum production, facial or body hirsutism, and acceleration of male pattern baldness (androgenetic alopecia).
• Gastrointestinal & Hepatic: Nausea, cholestatic jaundice, transient liver transaminase elevations, and in rare instances, peliosis hepatis or liver cell neoplasms during Bioniche Pharma treatment.
• Fluid & Electrolyte: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates, leading to potential peripheral edema and blood pressure elevations.
• Central Nervous System & Metabolic: Heightened aggression, anxiety, mood shifts, headaches, depressive symptoms, impaired glucose tolerance, and potential exacerbation of sleep apnea under Bioniche Pharma administration.

DOSAGE & PRESENTATION

Presentation: Bioniche Pharma Drostanolone Enanthate 250 mg/ml (10 ml multi-dose vial).

Dosing protocols for Drostanolone Enanthate by Bioniche Pharma must be individually tailored and administered under direct medical direction based on clinical goals, diagnostic lab parameters, and overall patient response.

STORAGE & HANDLING

Store Bioniche Pharma Drostanolone Enanthate in a cool, dry place between 15°C and 25°C. Protect from direct exposure to light. Do not refrigerate or freeze. Keep strictly out of the reach and sight of children.